Kostarox, 120 mg 7 pcs.

NSAID. Selective COX-2 inhibitor, in therapeutic concentrations blocks formation of prostaglandins and has anti-inflammatory, analgesic and antipyretic effect.

Indications

Symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis; pain and inflammatory symptoms associated with acute gouty arthritis; short-term treatment of pain associated with dental surgery.

Pharmacological effect

NSAIDs. A selective COX-2 inhibitor, in therapeutic concentrations, blocks the formation of prostaglandins and has anti-inflammatory, analgesic and antipyretic effects.

Special instructions

Use with caution when there is a history of ulcerative lesions of the gastrointestinal tract, Helicobacter pylori infection, in the elderly, in patients who have been receiving NSAIDs for a long time, with severe somatic diseases, dyslipidemia/hyperlipidemia, with diabetes mellitus, arterial hypertension, edema and fluid retention, smoking, in patients with CC less than 60 ml/min, with concomitant therapy with the following drugs: anticoagulants (for example, warfarin), antiplatelet agents (for example, acetylsalicylic acid, clopidogrel), corticosteroids (for example, prednisolone), selective serotonin reuptake inhibitors (for example, citalopram, fluoxetine, paroxetine, sertraline), for chronic alcoholism.

Active ingredient

Etoricoxib

Composition

1 tab. etoricoxib 120 mg

Pregnancy

The drug is contraindicated during pregnancy and lactation.

Contraindications

Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history).

Side Effects

From the digestive system: often – epigastric pain, nausea, diarrhea, dyspepsia, flatulence; sometimes – bloating, belching, increased peristalsis, constipation, dry oral mucosa, gastritis, ulcer of the gastric or duodenal mucosa, irritable bowel syndrome, esophagitis, ulcers of the oral mucosa, vomiting; very rarely – gastrointestinal ulcers (with bleeding or perforation), hepatitis.

Interaction

In patients receiving warfarin, administration of etoricoxib at a dose of 120 mg/day was accompanied by an increase of approximately 13% in MHO and prothrombin time.

Recommendations for use

The drug is taken orally at a dose of 60-120 mg 1 time/day.

Manufacturer

Cadila Pharmaceuticals Ltd, India